Send us a text

In this episode of the Life Science Success Podcast my guest is Michael Edwards, the founder and CEO of Bioinfo Solutions LLC, a data analytics company specializing in extracting insights from complex biological information. Dr. Edwards brings over two decades of experience in genomics, spanning from laboratory research to teaching data science and bioinformatics, with a passion for deciphering the genetic language of cells.

00:00 Introduction to Life Science Success Podcast

00:38 Sponsor Message: Bio on the Bayou 2025

02:12 Guest Introduction: Michael Edwards

02:36 Michael's Journey into Genomics and Bioinformatics

05:07 Key Milestones in Michael's Career

08:18 Founding Bioinfo Solutions

09:31 Diverse Projects and Client Engagements

15:38 The Role of Bioinformatics in Modern Research

22:28 Challenges and Insights in Data Analysis

27:00 Exploring Methodologies and Exciting Projects

28:05 Gene Expression as a Language

30:22 Future of AI in Bioinformatics

31:17 Networking and Data Visualization

32:20 AI and Automation in Various Fields

38:12 Importance of Statistics and Data Visualization

41:09 Broadening Skills and Tools in Bioinformatics

44:07 Inspiration and Concerns in Science

48:52 Concluding Thoughts and Reflections

Send us a text

In this episode of the Life Science Success Podcast my guest is Jesse Mendelsohn, a Senior Vice President at Model N with nearly two decades of experience in pharmaceutical pricing, revenue, and payer management. Jesse brings deep expertise in government regulation, including Medicaid and state pricing laws, making him a recognized leader in revenue optimization and compliance for life sciences and high-tech manufacturers.

00:00 Introduction to Life Science Success Podcast

00:40 Sponsor Message: Bio on the Bayou 2025

02:15 Guest Introduction: Jesse Mendelsohn

02:35 Jesse's Background and Career Journey

04:22 Complexities of Pharmaceutical Pricing

07:38 Career Milestones and Industry Changes

13:28 Current Role and Responsibilities at Model N

23:45 Innovative Projects at Model N

32:29 Leadership and Personal Insights

42:03 Conclusion and Podcast Wrap-Up

Send us a text

In this episode of Life Science Success, my guest is John McDonough, the Executive Chairman and CEO of Sunbird Bio. John is a seasoned life sciences executive with over 30 years of experience, known for his impressive track record of raising capital and creating substantial market value. He currently leads Sunbird Bio, a company at the forefront of developing innovative blood-based diagnostic tests for neurological disorders, particularly Alzheimer's disease. John's expertise extends beyond Sunbird Bio, as he also serves as chairman at Cytrellis Biosystems and BioPorto Diagnostics, and is the founder and president of the Crush Colon Cancer Foundation. With a history of successful IPOs, acquisitions, and mergers, John brings a wealth of knowledge and experience to our conversation about the future of neurological diagnostics and the life sciences industry.

Send us a text

In this episode of Life Science Success, my guest is RJ Kedziora, the co-founder of Estenda Solutions. With a career spanning over 30 years, RJ is a leading expert in healthcare technology and data analytics. We'll dive into his journey, the transformative work Estenda Solutions is doing, and the future of digital health.

• The podcast "Life Science Success" hosted by Don, a consultant in life sciences, features RJ Kedziora, the co-founder of Estenda Solutions, a company specializing in healthcare technology and data analytics.
• RJ Kedziora has a career spanning over 30 years and started Estenda Solutions in 2003 with Drew Lewis. The company initially focused on diabetes but has since expanded into other chronic conditions, offering solutions for Fortune 50 companies, startups, and government agencies.
• Estenda Solutions is unique in that it focuses on innovative product development, particularly in data analytics. They work with clients who have an idea but are not entirely sure how to execute it, rather than those who know exactly what they want.
• The company is ISO 13485 certified, indicating a strong quality assurance program. They take on larger projects and are audited annually to ensure they maintain high-quality processes.
• RJ Kedziora emphasizes the importance of data in healthcare, noting that the industry has evolved from having minimal data to dealing with billions of records. He is excited about the potential of AI and machine learning but also cautious about the rapid pace of technological advancements.

Send us a text

In this episode of Life Science Success, my guest is Hanns-Christian Mahler.  Dr. Mahler is Founder, CEO and Board Member at Ten23 health AG, the human-centric and sustainable pharmaceutical development partner.

1. Hanns-Christian Mahler is the Founder, CEO, and Board Member of ten23 health AG, a company specializing in sustainable pharmaceutical development. He has a background in pharmacy and has worked in various pharmaceutical companies and CDMOs (Contract Development and Manufacturing Organizations).

2. Mahler's leadership style focuses on building organizations from the ground up, emphasizing the importance of values, purpose, and motivation. He believes in creating a work environment that fosters joy and engagement among employees.

3. ten23 health AG differentiates itself from other CDMOs by its customer-centric approach and specialized expertise in developing difficult-to-produce products, such as high-volume blockbuster injectable products and products for subcutaneous self-administration.

4. Mahler is deeply concerned about climate change and is inspired by young activists like Greta Thunberg. His company is committed to sustainability, even registering for B Corp pending status and implementing various eco-friendly initiatives.

5. The best leadership advice Mahler has received emphasizes trust in employees. He believes that if you have the right people, there's no need to micromanage, and that trust fosters a more productive and engaged workforce.

Send us a text

In this episode of the Life Science Success Podcast, my guest is Lisa Sellers, PhD.   Dr. Sellers is the CEO of Vector Laboratories. She is an innovative and impactful leader with a truly unique approach to leading teams. She has deep expertise in running global life science tools businesses, developing new business strategies, and demonstrating excellent execution by leveraging her leadership style to harness the value of talent.

• The episode features Lisa V. Sellers, PhD, who is the CEO of Vector Laboratories. The discussion aims to explore Lisa's career journey, her role as CEO, and the future of life sciences.

• Lisa V. Sellers has been in the life sciences industry for over two decades. She has held various roles, from being a product manager in smaller businesses to being the CEO of Vector Laboratories. She is passionate about understanding the intricacies of the business she leads, as well as the needs of the customers they serve. She believes in leveraging innovation to meet these needs and enjoys developing multi-year growth strategies with her teams.

• Vector Laboratories is a company that specializes in bioconjugation, a technical capability that allows them to serve customers in various sectors like drug development, diagnostics, and life science tools. The company has been around for 45 years and is currently in a unique position where it combines the stability of a mature portfolio with the agility and growth potential of a startup.

• One of the key challenges Lisa faces as a CEO is managing people's ability to adapt to change, especially in a rapidly evolving industry. To tackle this, she has implemented comprehensive onboarding programs for new hires and emphasizes the importance of mentoring and community engagement. She also collaborates with local schools for community service, blending it with coaching and mentoring to broaden perspectives.

• Lisa is particularly excited about the future convergence of genomics and proteomics in life sciences. She sees this as a significant step toward a more integrated understanding of biology. She also believes that the key to navigating the future successfully is to be flexible and open to possibilities. She expresses concern about whether people and organizations will be able to adapt quickly enough to the changes that are bound to come in the field of life sciences.

Send us a text

In this episode of Life Science Success, my guest is Rajeev Sehgal.  Rajeev is the Sr. Director of Informatics at Azenta Life Sciences.  Rajeev is responsible for development and execution of Informatics strategy including product management, development, SQA, delivery, and support.

• Rajeev Sehgal discusses his experience with developing strategies that can be executed effectively. He highlights the importance of not only thinking about strategy but also having a clear understanding of how to execute it.
• Sehgal emphasizes the significance of focusing on the process rather than solely on the results. He notes that if the steps are right and repeatable, the results will show up eventually.
• Sehgal advises new leaders to be kind to themselves and not put too much pressure on themselves to deliver right away, especially in a new role or organization.
• He expresses concern about people hiding behind processes to stop progress and analysis paralysis, where people want more data than necessary before making a decision.
• Sehgal finds inspiration in doing something that will have a patient impact, working with colleagues who are doing amazing work, and seeing his children grow.

Key takeaways:

• Strategies must lead to good execution paths for their value to be realized.
• Focusing on the process and making it repeatable is key to achieving results.
• New leaders should be kind to themselves and not put too much pressure on themselves to deliver right away.
• People should not hide behind processes to stop progress, and analysis paralysis should be avoided.
• Doing something that will have a patient impact and working with colleagues who are doing amazing work can be inspiring.

Send us a text

In this episode of Life Science Success, my guest is Meredith Manuel.  Ms. Manuel is a proven leader with drive and determination in the scientific industry, specializing in global drug development and project management.  

Key Takeaways:

• Introduction to Meredith Manuel: Meredith Manuel is an accomplished leader with extensive experience in the scientific industry, particularly in global drug development and project management.

• Focus on Life Sciences: The podcast features a conversation between Meredith Manuel and the host, Don, who is a consultant specializing in helping companies within the life sciences sector enhance their strategies, processes, and technologies.

• Exploring Spatial Biology: Meredith discusses her role at "enable" where she manages the commercial division of a company focused on spatial biology. Spatial biology involves analyzing markers and molecules in the context of tissue, allowing for a deeper understanding of cell interactions and disease mechanisms.

• Impact on Drug Development: The application of spatial biology in drug development is highlighted, emphasizing the importance of moving beyond traditional single biomarker approaches. Integrating various data sets and understanding complex interactions within tissues is seen as crucial for advancing drug development.

• Leadership and Collaboration: Meredith also shares insights about leadership and collaboration, encouraging individuals to advocate for themselves and promote diversity of perspectives. She emphasizes the need for open communication within teams and across disciplines, especially in the dynamic field of life sciences.

Details:

Meredith Manuel is introduced as a guest on the "Life Science Success Podcast." The podcast is hosted by Don, a life sciences consultant focusing on improving companies' strategies, processes, and technology within the life sciences sector. Meredith has a strong background in the scientific industry, with a focus on global drug development and project management. She has a lifelong fascination with science, dating back to kindergarten when she first became interested in the field. Her career has spanned different areas of drug development, and she is particularly passionate about spatial biology, a cutting-edge technology that involves analyzing markers and molecules in tissue context.

Meredith's role at "enable" involves managing the commercial division of a company that specializes in spatial biology. She explains that spatial biology allows researchers to analyze cell interactions and disease mechanisms by studying markers in the context of tissue. This technology enables a more comprehensive understanding of disease processes and has applications in challenging areas like oncology and immunology. Meredith emphasizes that this approach goes beyond the traditional single biomarker paradigm, enabling a deeper understanding of complex biological processes.

Meredith discusses leadership and collaboration, drawing from her extensive experience. She encourages individuals, especially women, to advocate for themselves and share their ideas openly. She shares a story about a female boss who advised her to be her own advocate and speak up. She believes that diverse perspectives are crucial for innovation and problem-solving. Meredith underscores the importance of listening, collaboration, and communication in achieving successful outcomes within teams.

The conversation concludes with discussions about the challenges and potential future directions of spatial biology and drug development. Meredith expresses her desire to contribute to

Send us a text

In this episode of Life Science Success, I am interviewing one of the world’s leading business thinkers, Dr. David Burkus’ forward-thinking ideas and bestselling books are helping leaders build their best team ever.

• Dr. David Burkus discusses the challenges of remote and hybrid work environments and the importance of deliberate leadership
• He emphasizes the need for fair feedback, giving feedback in proportion to how someone is doing
• Dr. Burkus also stresses the importance of micro praises and the need to be deliberate about recognizing employees' successes
• He believes that many organizations are approaching remote and hybrid work in the wrong way and need to have a broader conversation about the type of work that should happen in the office versus remotely
• Dr. Burkus is inspired to make work not suck and wants to help organizations tap into their employees' potential
• He also discusses his course, "Build Your Best Team Ever," which provides research-based actions for team leaders to improve their teams' dynamics and productivity

Send us a text

In this episode of Life Science Success, my guest is Ketan Mehta, the founder and CEO of Tris Pharma. Under his leadership, Tris Pharma has developed many innovative technologies, launched new products, and established itself as a leader among technology-driven pharmaceutical companies. 

• Ketan Mehta discusses the importance of being open to change and feedback in building successful companies
• Patient feedback has directly influenced Tris Pharma's product development
• Ketan Mehta believes that the pharmaceutical industry will evolve significantly in the next decade, particularly with the rise of personalized medicine and digital health
• He offers advice for aspiring entrepreneurs in the life sciences, emphasizing the need for clear motivation, commitment, and a focus on making a positive impact
• Ketan Mehta is excited about the future possibilities and the potential for significant change in the next few decades

Send us a text

This week on the Life Science Success podcast, my guest is Thomas Farb-Horch.  Thomas is the CEO of Thrive Bio.  He has been involved in the founding of 18 pharmaceutical, biotech, medtech, software, and AI companies, 7 of which have been unicorns. Currently, he is CEO and Co-Founder of Boston-based Thrive Bioscience, which commercializes instruments and software for a critically important but neglected area of life sciences, which is imaging, analytics, and automation of cell culture, cell-based research, and cell therapeutics.

• Thomas Forest Farb-Horch has experience automating cytology labs and now seeks to improve cell culture labs through Thrive.
• Thrive aims to improve the low chances of therapeutics getting from bench to patient by transforming cell biology.
• Thrive's technology collects large, comparable data sets that make better cells, which is important for bringing cell therapeutics to the market.
• Thrive's data sets and images are valuable to researchers because they can see things that they never saw before and make faster decisions.
• Thrive is transforming viral plaque assay, which is the standard way of studying viruses, and can now track plaques from day 2 instead of waiting for weeks.
• Thomas is concerned about divisiveness, duality, and false dualities, and the lack of equality of opportunity, education, and health.
• Thomas is excited about solving big, ignored problems and changing the world.

Send us a text

In this episode of the Life Science Success Podcast, my guest is Artem Britchenko.  Artem is the CEO of Platforce, which helps companies that interact with healthcare professionals and care about the efficiency and compliance of these interactions. He has been working in the B2C Pharma industry, helping companies improve their sales force effectiveness, customer engagement, and customer centricity.

• Don Davis, PhD, MBA interviews Artem Brytchenko, CEO of Platforce
• Platforce is a CRM solution tailored to the unique needs of the life sciences industry
• The solution includes closed loop marketing, remote capabilities, consent collection, distributor order optimization, and more
• The biggest challenges faced by Platforce include constant innovation and adaptation, scaling operations, and managing a global, distributed team
• The biggest opportunities include the rapid digital transformation of the life sciences industry, expanding to new geographies and markets, and serving adjacent sectors within healthcare
• Artem is inspired by his team, challenges, and family, concerned about the rapidly changing technological landscape and global complexities, and excited about fostering innovation and collaboration, technological advancements, and personal growth and happiness

Send us a text

In this episode of Life Science Success, my guest is Rohit Sood  EVP, COMPLETE Commercialization at EVERSANA.  He is a life sciences strategy and operations executive with a passion for developing teams and solving business challenges. Track record of driving topline business growth while identifying significant operational efficiencies in PE-backed, startup, and publicly-listed organizations.

• Rohit Sood and Don Davis discuss challenges faced by organizations during the commercialization phase
• Eversana helps smaller biotechs evaluate the process of commercialization and provides support through it
• Good leadership inspires Rohit, and he values transparency and clarity in decision-making
• Short-term thinking and not listening to advisors concerns Rohit
• Traveling and food excite Rohit

Send us a text

Join us on the Life Science Success podcast as we dive into the world of clinical trial innovation with Richie McCann, Head of Global Sales for Site Payments at Greenphire. Discover how this pioneering company is transforming financial management and patient support in global clinical trials.

In this episode, we explore:

• Greenphire’s mission and impact on the clinical trial industry

• Innovative solutions for streamlining trial processes

• Balancing technology with participant experience

• The future of financial management in clinical research.

Don’t miss this insightful conversation on the cutting edge of life sciences. 

Send us a text

In this episode of Life Science Success, I am joined by Daniel Thadani the Head of Retail and Tenders for IPCA Laboratories Limited.  Daniel is based in Kyiv, Ukraine 🇺🇦.  He is responsible for  business promotion and development, sales forecasting, distribution management, marketing coordination with head office, pricing, product registration through a third party, team hiring, and management.

• Daniel Thadani worked as a country head in Kazakhstan for five and a half years
• He describes the differences in medical affairs, regulatory, people management, distribution, and the overall landscape of pharma in Central Asia
• Thadani emphasizes the importance of trust and integrity in leadership
• He works for IPCA Laboratories, a top-notch pharma company that produces branded generic products with 350 formulations and 80 APIs in various therapeutic areas
• IPCA has a solid footprint in Africa, South America, and Southeast Asia and is a world leader in APIs
• Thadani discusses the resilience of the pharma business in Ukraine during the COVID-19 pandemic and war
• He is concerned about indecency and political approaches in people, as well as discrepancies in numbers
• Thadani is excited by complex situations with a positive impact on his immediate ecosystem

Send us a text

In this episode of Life Science Success, my guest is Nusqe Spanton.  Nusqe is the founder and CEO of Provectus Algae. He is an aquaculture and algae expert with nearly two decades of experience working in international aquacultural production, marine biotechnology, and corporate management.

• Nusqe Spanton discusses the potential of marine microorganisms to produce commercially valuable compounds.
• The company, Provectus, is focused on developing products for food, agriculture, and cosmetics, as well as oral fertility treatments.
• The company is still in an early phase of development and has around 30 employees.
• Spanton emphasizes the importance of making quick and decisive decisions as a leader, especially in a startup environment.
• He also stresses the need to move quickly in addressing environmental concerns.
• Spanton is inspired by his children and the potential of the younger generation to effect change.
• He is excited about building a great business with like-minded individuals and being a problem solver.

Send us a text

In this episode of Life Science Success, my guest is John Alderete. Dr. Alderete has successfully applied his wide range of experience and formal training to the evaluation, financing, formation, and operation of diagnostics and medical device technology companies.

• Don Davis and John Alderete discuss pitching scientific research to investors
• Davis emphasizes tailoring pitches to the audience and understanding investors' perspective
• Alderete stresses the importance of having the right team and being honest about limitations
• Alderete expresses concern about lack of progress in biological surveillance and potential for future pandemics
• Alderete is excited about modern tools and technologies available to younger generation of scientists
• The conversation offers insights on challenges of pitching research, importance of team, and need for better pandemic preparation
• It highlights exciting possibilities in modern tools and technologies for younger scientists.

Send us a text

In this episode of Life Science Success, my guest is Dr. Helen Torley.  Dr. Torley is the President and CEO of Halozyme. Halozyme's innovative and disruptive solutions provide new therapeutic options that could significantly improve the patient experience by changing how treatments are delivered. 

• Dr. Helen Torley, CEO of Halozyme, discusses the company's dedication to improving patient experiences and outcomes through their research and development of monoclonal antibodies and small molecules.
• Halozyme places a strong emphasis on corporate culture, including cross-functional collaboration and community outreach.
• Dr. Torley shares how the book "The Five Dysfunctions of a Team" has influenced her leadership style.
• Dr. Torley is inspired by the innovative ideas and enthusiasm of her team members.
• She expresses concern about the impact of remote work on creativity, problem-solving, and personal development.
• The company is focused on putting patients at the center of their mission.
• They have a strong focus on community outreach, with 70% employee participation in volunteering events.
• She shares a personal story about a family member's experience with cancer treatment to underscore the importance of improving patient experiences.
• This episode of the Life Science Success podcast provides insight into the innovative solutions Halozyme is developing and their commitment to patient-centered care.

Send us a text

In this episode of Life Science Success my guest is Kristofer Mussar.   Kristofer graduated from University of Georgia with a PhD in Molecular Genetics where he focused on Epigenetics and Evolution. He simultaneously obtained his MBA from the Terry College of Business.  He is currently the Managing Director and COO of VectorBuilder Inc.

• Kristofer Mussar, PhD, discusses his company Vector Builder and their innovative gene delivery methods.
• Vector Builder's platform is free to use and includes a design team for gene delivery methods.
• They are working on several R&D projects, including a capsid evolution for novel capsids, a bacterial backbone-free plasmid, and antibody-conjugated lipo nanoparticles with mRNA.
• Vector Builder emphasizes collaboration and treating researchers as collaborators.
• Mussar believes in the importance of genetics and personalized medicine.
• Vector Builder has a new software-based platform called Vector B in development.

Send us a text

In this episode of Life Science Success my guests are Rahul Sharma, the co-founder and CSO of Scienetix, a company dedicated to enabling Molecular Diagnosis. Dr. Sharma is a board-certified laboratory director and technical lead for Next Generation Sequencing (NGS) and PCR-based assay development and clinical testing. He has developed multiple Molecular Diagnosis tests and translated them into clinical testing. 

Additionally, We are joined by Rob Carpenter PhD, MBA the CEO of Scienetix.  Rob is a healthcare executive and educator with over 25 years’ experience in developing, managing, and assimilating healthcare companies. He is distinctly skilled in business development and various business growth strategies. He is founder and current CEO of Advanta Genetics, a highly complex clinical and research laboratory accredited by the College of American Pathologists with concentration in infectious disease molecular genomics and Scienetix, a bioscientific company centered around products to optimize molecular genomic
workflows.

• In the podcast, Dr. Sharma and Dr. Carpenter talk about the healthcare industry's need to optimize workflow and reduce costs in laboratory testing.
• Their company, Scienetix, is working on developing extraction-free tests that will eliminate the need for sample pre-processing and make testing more accessible and cheaper for labs.
• They are also focused on increasing the multiplex capability of PCR reactions, which will allow labs to test for more targets in a single reaction.
• Dr. Sharma and Dr. Carpenter also discuss their leadership styles and offer advice on being reliable, thinking about the application of science, and staying creative.
• They express concern about the growing distrust of science and the spread of misinformation, particularly in the age of social media.
• What excites them most is the opportunity to solve scientific challenges and create products that have a societal impact.

Send us a text

In this episode of Life Sciences Success, my guest is Sharon Rogers the CEO of AmyriAD.  Sharon brings the strength of her 35 years of pharmaceutical experience to AmyriAD. She is best known as the worldwide leader and development strategist for the highly successful AD treatment, Aricept. Aricept has been the standard of care for more than 20 years, and no other AD program has produced more compelling results.

• Sharon L. Rogers, a research scientist, talks about a new drug for Alzheimer's disease
• The drug, AD101, is designed to improve cognition and global function in Alzheimer's patients
• It is a cholinergic drug, but its action is limited to the brain, making it more effective than other cholinergic drugs
• The drug has gone through phase two trials and is now moving into phase three
• Rogers also discusses her experience as an expat in Japan and the importance of resilience and leadership
• She expresses concern about complacency and outrage fatigue
• Rogers is excited about the potential of Gen Z to effect change

Send us a text

Today on the Life Science Success podcast my guest is Sal Buscemi.  Sal is a notable figure in the world of finance and real estate, has made a name for himself through his impressive portfolio of investments and his leadership roles in various investment offices. Currently serving as the CEO and Co-Founding Partner of HRN, a private multi-family investment office, as well as the CEO for Dandrew Partners Capital Management.

• Sal Buscemi discusses the importance of understanding the science and evaluating user feedback effectively
• He advises making investment opportunities attractive to investors, as they are unlikely to focus on the math
• Sal emphasizes the significance of building relationships and networking, as it is important for building a brand and reputation
• He expresses concerns about the potential destabilization of the petro dollar and the impact it might have on the strength of the country
• Sal mentions that he enjoys building things, meeting new people, and making an impact in the life sciences industry

Send us a text

his week on the Life Science Success Podcast, my guest is Surekha Karudapuram, VP Commercial Operations - Isolation Bio Inc.  Surekha is an innovative, technically-savvy and accomplished product & marketing executive with 15+ years of experience, including leading the development and execution of corporate product management and marketing programs to support long term strategic, commercial, and financial goals.

• Surekha Karudapuram is a product manager who leads marketing, product management, and commercial operations teams.
• Isolation Bio provides a high throughput microbial cultivation platform and services to accelerate the time to discovery for microbiome R&D and product development.
• Isolation Bio's platform is automated, scalable, and helps to generate microbes that could be used in therapeutics or bio fertilizers.
• Surekha is concerned about the ethical and regulatory guardrails in the fast-moving life sciences space and the communication of scientific discoveries to the general public.
• Surekha is excited about the possibilities in the microbiome space and believes that microbiome scientists in both academia and industry are going to make exciting discoveries that will translate into great benefits for humanity.

Send us a text

In this episode of the Life Science Success podcast my guest is Jeremy Stackawitz.  Jeremy has over 25 years of healthcare industry experience and 15 years of diagnostics experience. Before joining Senzo as CEO, from 2009-2021 Mr. Stackawitz held roles of CCO, President, and CEO at Quotient (QTNT), helping lead the company from start-up to IPO. 

Jeremy Stackawitz, CEO of Senzo Biosciences, recently discussed the current state of the diagnostic industry. The industry faces several challenges and opportunities, including the need for accessibility and cost reduction. Stackawitz notes that the COVID-19 pandemic has had a significant impact on the industry, with many companies struggling to stay afloat.

One of the key topics Stackawitz discussed was the advantages and disadvantages of small versus large companies in the industry. While smaller companies may have more agility and flexibility, larger companies may have more resources and established relationships with key players in the industry.

When asked to share his favorite leadership advice, Stackawitz emphasized the importance of building a strong team and fostering a culture of collaboration and innovation. He also shared what inspires and concerns him in his work, including the potential to make a positive impact on people's lives through improved diagnostics, as well as the challenges of navigating a complex and constantly evolving industry.

Overall, Stackawitz's insights provide a valuable perspective on the diagnostic industry and the opportunities and challenges it faces. By addressing issues such as accessibility, cost reduction, and the advantages and disadvantages of different types of companies, the industry can continue to innovate and improve the lives of people around the world.

Send us a text

In this episode of Life Science Success, my guest is John Houston, Ph.D., the Chairperson, Chief Executive Officer, and President of Arvinas. With over three decades of experience in drug discovery and development, Dr. Houston brings valuable insights into pioneering protein degradation therapeutics and the challenges of leading a cutting-edge biotech company.

Send us a text

In this episode of Life Science Success I interviewed Samantha Dale Strasser - CSO & Cofounder at Pepper Bio at #bio2023.  

• Samantha Dale Strasser is the Chief Science Officer and co-founder of PEPPER Bio.
• PEPPER Bio is the world's first trans omics analysis company.
• Trans omics involves analyzing a wealth of biological information from genomics all the way up to more functional data of phospho proteomics.
• PEPPER Bio is able to see more relevant disease insights about how to best treat disease and how to characterize potential drugs that can be used as therapeutics.
• PEPPER Bio has four contracts and is actively seeking partnerships with pharma.
• The Compass platform is PEPPER Bio's computational technology that provides the computational ability to analyze genomic, transcriptomic, proteomic, and phos proteomic data in a novel way through trans omics to best support partners' drug discovery questions as well as our own pipeline.
• PEPPER Bio can work with partners early on from characterizing the disease to answer what targets are best to go after for it to staying with them through the drug discovery process to bring the power of Ranomics all the way through to the clinic.
• PEPPER Bio sees potential for shortening the timelines for drug discovery, notably around the ability to very early on select drug candidates that are most likely to be successful in the clinic.
• Trans omics can have an impact on the massive failure rate at the very end of the drug discovery process by allowing for early identification of potential concerns of toxicity.

Send us a text

Today on the Life Science Success podcast my guest is Oksana Bovt.  Oksana is the founder of Theoria Creative, an agency that develops unique fundraising materials enabling biotech and life sciences clients to clearly and succinctly articulate their unique message and value when raising funds, soliciting partnerships, pitching at roadshows, or presenting to prospective buyers.

• Oksana Bovt helps biotech companies communicate their scientific innovations to investors and potential partners.
• She emphasizes the importance of crafting an interesting story to grab investors' attention.
• Her company, Theoria Creative, is known for translating complex science and creating visual and illustrative materials, such as investor decks, scientific illustrations, and scientific animations.
• Theoria Creative works mostly on referral and helps companies that are ready to communicate effectively and have a clear direction.
• Oksana Bovt's background in science and advertising helps her to understand and communicate complex scientific concepts effectively.
• Theoria Creative helped a company with a broad oncology pipeline clarify their story and focus on approaching oncology and cancer holistically, resulting in a successful oversubscribed round and public offering.
• Oksana Bovt's best career advice is to understand oneself first and pursue what one is good at and passionate about.
• She is inspired by her clients and concerned about the global economy and the safety of her team in Ukraine.
• Her dog excites her and reminds her to take breaks and enjoy the outdoors.

Send us a text

In this episode of Life Science Success my guest is Mason Ailstock the CEO of Rowen Foundation.  The mission of Rowen is to be a catalyst for education, research, innovation and transformation through the creation of a global destination which recognizes stewardship of the land as the cornerstone of an inspired community.

• Mason Ailstock is part of a foundation that oversees the covenants, the programming, the partnerships, attracting investors, and more.
• They want to create a place for companies and people to grow, and for startups to have access to opportunities.
• Rowan is a 50+ year project that aims to create a platform for other people to step up and have greater access to opportunities and the vision that they have.
• They are working on infrastructure and doing things that are very different from what the Department of Transportation typically does.
• They are hoping to create a place where implementation is a primary objective of doing as part of the culture, and where implementation is a primary objective of doing.
• The initial infrastructure will be finished in the second quarter of 2024, which will include the first two miles of complete streets designed in construction, ribbon cutting, opening of the roadway.
• They are working towards a sustainable and environmentally friendly development.
• They have been meeting with companies that have existing relationships or an interest in Georgia, and most of the companies they're talking to are internationally based.
• They have sites that could be 2 acres to 50+ acres, and most of the companies they're talking to are looking for a North America, either headquarters or R&D innovation, foothold.
• They are looking to connect startups to Georgia, locate, grow, attract investments, scale up.
• They are hoping to have multi-tenant buildings, multi-tenant lab space, and mixed-use components in the future.

Send us a text

In this episode of Life Science Success my guest is Kent Wakeford.  Kent is the co-founder and Co-CEO of Form Bio an organization that focuses on providing computational life sciences and AI solutions to biotech and biopharma companies.

• Form Bio was spun out of Colossal Bioscience, and focuses on providing computational life sciences and AI solutions to biotech and biopharma companies
• Form Bio announced a partnership with Google as part of the Google multi omic suite of products
• Form Bio's computational platform focuses specifically on cell and gene therapy, and is designed to optimize the manufacturability of these therapies
• Kent Wakeford is inspired by the potential of AI to transform the industry, and is concerned about the need to change the infrastructure to make drug development more efficient
• Kent Wakeford believes that collaboration is key to solving industry-wide problems, and that the speed of innovation is transformative

Send us a text

In this episode of Life Science Success my Guest is Alex Zhavoronkov.  Alex is the CEO Insilico Medicine an AI-powered drug discovery company.

• Insilico Medicine has progressed three internally-derived assets into human clinical trials.

• Insilico Medicine has discovered over 30 other programs in different stages.
• Insilico Medicine incorporates three engines in their platform: biology, chemistry, and clinical.
• They generate normal molecules with desired properties using 42 generative engines.
• They have a system that predicts clinical trials outcomes.
• Insilico Medicine’s main strategy is partnering with pharma companies at the preclinical candidate stage.
• They value patient first, relentless innovation, and transparency and integrity.
• Alex's biggest concern is human tendency to prioritize unimportant things over important ones.
• Alex is excited about large language models, multimodal generative AI, robotics, and quantum computing.

Send us a text

In this episode of Life Science Success my guest is Alex Chen.  Alex is the President of Overseas Operations at uBriGene Biosciences Inc.

• He has diversified experience, having worked in various industries such as mining, real estate, and investment banking before joining uBriGene Biosciences Inc.
• uBriGene Biosciences Inc. is a biotech company that provides services ranging from upstream to downstream, including QC testing
• The company is focused on innovation and utilizes the most up-to-date technologies to provide cost-effective and quality products
• uBriGene Biosciences Inc. has sites in the US and China, and its core competency is research and development
• The company aims to be a partner with its clients and grow with them
• uBriGene Biosciences Inc. has over 500 employees globally and has raised $100 million to date

Send us a text

In this episode my guest is Jason Bock PhD.  Jason is the CEO of CTMC / A joint venture between Resilience and MD Anderson Cancer Center.

• Jason Bock has been in biotech and biopharma for over 20 years, mostly in Biologics development.
• He founded Ctmc, a technology platform to industrialize cell therapies and bring them into the MD Anderson Clinic.
• Ctmc is a joint venture between MD Anderson and National Resilience.
• Ctmc partners with preclinical biotech, MD Anderson faculty, and Factus to provide a capital-efficient model to bring impactful single dose curative treatments to patients.
• Ctmc has filed three INDs in the first six months since it spun off on novel cell therapies brought into the clinic.
• Ctmc has progressed on the seven clinical studies that it supports.
• Ctmc recently announced that it was the recipient of a $9.1 million grant to help develop cell therapy platforms and improved ways of making these cell therapies.
• Jason is inspired by the patients and patient-centricity. He is concerned about the challenges, logistical and manufacturing challenges with autologous cell therapy. What excites him is the potential to transform healthcare and be single-dose curative treatments.

Send us a text

In this episode of Life Science Success my guest is Benedicta Durcan, CEO of Afrobodies. Her work experience has been in complex industries and environments spanning 12 years in Private Sector globally and 8 years in Public Sector in South Africa. I am an Upstream Oil & Gas and Maritime industry Specialist. I am an innovator and contributor in the field of STEM.

• Benedicta Durcan is the co-founder and CEO of Afro Body, a biotechnology company in South Africa that produces biological products for global consumption, including novel antibodies.
• Benedicta's background is in chemical engineering, and she has worked in the oil and gas and energy sectors before starting Afro Body with co-founder Dr. Peter Durkin.
• Afro Body's antibodies are recombinant alpaca antibodies used in life science research, diagnostics, and therapeutics for various diseases.
• Benedicta's role involves stakeholder management and engagement, raising initial grant funding, building a team, finding collaborators and partnerships, and expanding the company's global reach.
• Companies and researchers come to Afro Body for custom antibodies to study specific proteins, detect or test for the presence of molecules or bacteria, or develop treatments for diseases.
• Benedicta is inspired by the passing it on philosophy and believes in leaving a legacy for her children.
• Benedicta is concerned about the geo policies, global economics, and competing priorities that exacerbate inequalities, particularly in access to lifesaving medicine.
• Benedicta is excited about traveling and continually expanding her world and perspective.

Send us a text

In this episode of Life Science Success my guest is Jason Mundin, MBA who is the CEO of Ubiquigent.  Jason has over 30 years’ experience in the pharmaceutical and biotechnology industries. He joined Ubiquigent in 2015 as Commercial Director, becoming Managing Director in 2018 and CEO in 2021. 

• Jason Mundin is the CEO of Ubiquigent, a biotech company that focuses on drug discovery
• They have taken the company from a loss-making biotech to a profitable one.
• They are now focused on becoming a drug discovery-focused therapeutics company.
• They are actively engaged in securing inward investment.
• They are concerned about the state of funding for the life sciences industry.
• They are excited about the potential of their programs and the value they can bring to the industry.
• They believe that innovation is necessary due to limited resources and are constantly looking for ways to be innovative.
• They are excited to attend conferences and connect with people who are interested in their work.

Send us a text

In this episode of the Life Science Success Podcast my guest is Pavel Printsev.  Pavel is the Director of Business Development at Bridge Biotherapeutics. Prior to joining Bridge in early 2021 he was working at a South Korean VC firm. Pavel’s academic background is in Organic Chemistry and worked as a Research Scientist for several years. Since then, he has been active in advancing scientific development through global partnership, collaboration and investment between South Korea and the rest of the world.

• Bridge Biotherapeutics is a small to mid-size Biotherapeutics company founded in 2015.
• They have clinical-stage assets in nonsmall cell lung cancer, ulcerative colitis, and idiopathic pulmonary fibrosis.
• They also acquired a next-generation biosensor detection company, which is a thousand times more sensitive than the current commercial ECL biosensor device.
• Bridge Biotherapeutics is focused on maximizing resources and following the path where they see the most opportunity.
• Pavel Printsev is inspired by people who have become masters in their respective fields and are dedicated, motivated, ambitious, and do not give up.
• Concerns include the gap in research and unmet medical needs for indications that may not be profitable.
• Pavel is excited about the advancements in AI and deep learning, gene editing, and precision medicine.

Send us a text

In this episode of the Life Science Success Podcast, we dive deep into the world of health communication with Michelle Bridenbaker, COO of Unbiased Science at Vital Statistics Consulting. Michelle shares her journey from nursing to leadership in health communications, offering insights into the challenges of conveying accurate scientific information in today's media-saturated landscape. She discusses innovative strategies for pharmaceutical companies to effectively reach healthcare professionals and combat misinformation. Michelle also explores the role of digital transformation in health communication and provides a glimpse into the future of scientific engagement. With her unique perspective on balancing regulatory compliance and dynamic audience engagement, this episode offers valuable insights for anyone interested in the intersection of healthcare, communication, and technology.

Send us a text

In this episode of Life Science Success, my guest is David Baram.  David Baram is the co-founder and CEO of Emendo Biotherapeutics. David has taken Emendo from the pre-seed stage through multiple financing rounds and a successful acquisition in 2020.

• Don Davis, PhD, MBA interviews David Baram, PhD, CEO of Emendo Biotherapeautics
• Mendo is focused on developing gene editing therapies for rare and prevalent diseases, including cardiovascular diseases.
• They discuss the challenges of managing a company with different interests at play, including investors and patients.
• They touch on the potential of AI and the need for regulation and control.
• David shares his motivation and excitement in achieving his goals and seeing his inventions materialize.

Send us a text

In this episode of the Life Science Success podcast my guest is Robert Bruchet.  Robert is a General Manager - Middle East & Africa at Ethypharm. He applies a deep understanding of commercial levers to maximize the P&L and drive growth. Demonstrated leadership across multiple functions (marketing, sales, market access, and public affairs) and general management.

• Rob Bruchet discusses his work in the pharmaceutical industry in Africa and the Middle East
• He talks about the challenges of expanding a business in that region, particularly with established brands and price pressure
• Bruchet emphasizes the importance of diversity in those markets, noting the wide range of languages and cultures
• He also shares his experience working in Dubai and the sense of adventure that drove him to move there
• Bruchet enjoys the opportunity to create something new and make changes in his work, and he is motivated by the drive and ambition of younger people in the industry

Send us a text

The interview discusses challenges faced by at-home diagnostic companies, including differentiation from competitors, market education, and lack of direct billing code. Opportunities for growth in the at-home healthcare market are highlighted, while concerns include the blurring of personal and work life and potential for overcommitment. Exciting developments in technology, particularly in digital health and medtech, are noted as improving quality of life for individuals.

• Challenges faced include differentiating from competitors, educating the market, and lack of direct billing code for at-home diagnostics
• Opportunities include growth as at-home healthcare becomes more mainstream
• Concerns include the blurring of the line between personal and work life and the potential for overcommitment
• Exciting developments in technology, particularly in the digital health and medtech fields, improving quality of life for individuals

Send us a text

In this episode of the Life Science Success Podcast my guest is Chris Anderson.  Chris is a seasoned Pharmaceutical Professional with more than 20 years of experience in multiple fields within the Industry.

• Don Davis and Chris Anderson discuss the regenerative medicine industry
• Chris highlights the need for partnerships between companies and government entities
• The challenges of ensuring compliance and patient safety in a new and evolving industry are discussed
• Chris talks about being inspired by the people and ideas in the industry
• They both express excitement about the potential for future advancements in regenerative medicine and other areas like AI.

Send us a text

In this episode of the Life Science Success podcast, my guest is Dr. Scott Wagers.  Scott is the CEO of BioSci Consulting, the author of Assembled Chaos, and the host of Beyond Publications podcast. (Consortium Whisperer)

• Dr. Scott Wagers helps people develop consortium projects to speed up the realization of the future of medicine.
• The translational gap is the delay between research findings and clinical implementation, and it takes about 17 years to cross.
• The bottleneck in the translational gap is the resistance to change and the lack of adoption.
• AI has the potential to free humans to focus on what they're really optimized for, which is creativity, pattern recognition, and working together.
• The human mind is optimized for certain things that AI can free us to focus on.
• Collective thinking of a bunch of different people is a very powerful computer in its own right.
• Leadership isn't just at the very top level; it's at every level, down to the PhD student who writes an outline or an SOP.
• Beyond Publications is a podcast about going beyond publications and pushing through the translational gap.
• Patients inspire Dr. Scott Wagers, and the translational gap concerns him.
• The dynamic of collective thinking and working together excites Dr. Scott Wagers.

Send us a text

This week on the Life Science Success Podcast my guest is Nathan Clark.  Nathan is the co-founder of Ganymede and is passionate about biotechnology. He is at the frontier of biology and engineering, and has merged his profound knowledge in this field with business development to reimagine data infrastructure in the life sciences.

• Nathan Clark discusses his company's goal to become the infrastructure for the life sciences industry
• The industry is moving slowly in terms of digital transformation and data integration
• The complexity of data in the life sciences industry is a unique problem that requires a science of managing that complexity
• Instrument manufacturers are inhibiting connectivity by putting all their data into different formats
• The goal is to create a centralized data lake that can be mapped together and linked
• The complexity of the industry and the slow pace of digital transformation concerns Nathan Clark
• Nathan Clark is excited about the potential for scientific advancements in the life sciences industry, including understanding epigenetics and how biological systems interact with each other

Send us a text

In this episode of Life Science Success, my guest is Zach White.   Zach is the host of the Happy Engineer Podcast, and he is also a career coach who is helping thousands of engineering leaders reach the next level without suffering burnout. 

• Zach White discusses the challenges that engineers face in their careers, including continually increasing demands and the need to balance leadership development with technical knowledge.
• He also discusses the importance of mindset and coaching to help engineers achieve their goals and find fulfillment in their work.
• Zach is inspired by seeing clients take courageous steps and achieve what they previously thought was impossible.
• He is concerned about the impact of financial systems and policies on the economy and the need for continual learning in the face of rapidly advancing technology.
• Zach is excited about travel and the opportunity to experience new places and cultures.
• The Happy Engineer Podcast, hosted by Zach, focuses on helping engineers build their careers, balance their lives, and find happiness along the way.

Send us a text

In this episode of Life Science Success, my guest is Gino Martini.  Gino is the CEO of the Precision Health Technologies Accelerator (PHTA Ltd).  Previously, he was the Chief Scientist of the Royal Pharmaceutical Society. 

Key Topics Covered: 

• Description of an accelerator program for health tech companies
• The importance of social interaction for innovation in a hybrid work environment
• Excitement for precision medicine and personalized treatment plans
• Interest in bedside manufacturing and its potential for patient care
• Challenges in the life sciences industry, such as the lack of lab space and access to skills
• Opportunities in precision medicine, bedside manufacturing, and the microbiome

Send us a text

• AJ Melet is the CEO of a startup biotechnology company Ronawk Inc.
• Ronawk Inc’s technology involves growing cells in a tissue mimetic substrate called bio blocks.
• The cells grow in 3D and form their own micro tissues, which can be used to manufacture new therapies.
• Roanoke's technology has potential applications in tissue engineering and scaling the production of biological factors.
• The biggest challenges Roanoke is currently facing are building a new lab and getting people to understand the new technology.
• AJ Melet is inspired by people who serve others, concerned about our ability to connect in a digital world, and excited by people tackling big challenges.

Send us a text

In this episode of Life Science Success, my guest is Katherine Vega Stultz.  Katherine is the President and CEO of Ocelot Bio, a clinical stage company focused on developing innovative therapeutics to significantly improve outcomes for patients with end-stage liver disease.

In this episode of Life Science Success my guest is Katherine Vega Stultz and we touch upon a number of topics, including the non-linear path of career growth, the importance of being a generalist in a specialized industry, and the challenges and opportunities facing Ocelot Bio, a private venture-backed company that is focused on liver disease. Stultz talks about the importance of team collaboration, transparency, and communication, and how her experiences have helped her develop a continuous improvement mindset. She also discusses her passion for tackling complex problems that impact people's lives and how she is excited to be in a position of leadership that advocates for diversity and talent.

• Non-linear path of career growth
• Importance of being a generalist in a specialized industry
• Challenges and opportunities facing Ocelot Bio
• Importance of team collaboration, transparency, and communication
• Continuous improvement mindset
• Passion for tackling complex problems that impact people's lives
• Advocacy for diversity and talent in leadership

Send us a text

Broderick Jones is a seasoned executive with 25 years of experience in Healthcare, Life Sciences, and Financial Services, known for driving growth and operational excellence across key business functions. Currently serving as a senior leader at Verista, he brings his expertise in compliance and validation services to the pharmaceutical, medical device, and biotechnology industries.

Send us a text

In this episode of the Life Science Success podcast, my guest is Martin-Immanuel Bittner 𝘔𝘋 𝘋𝘗𝘩𝘪𝘭 𝘍𝘙𝘚𝘈. Martin-Immanuel is the CEO & Co-Founder of Arctoris, a biotech platform company powered by robotics and machine learning based in Oxford and Boston.

Martin-Immanuel Bittner is the CEO and founder of Arctoris, a biotech platform company focused on drug discovery with partnerships worldwide. 

• Martin-Immanuel Bittner is the CEO and founder of Arctoris, a biotech platform company powered by robotics and machine learning based in Oxford and Boston
• The company's focus is on drug discovery, and it has partnerships with dozens of biotech and pharma companies worldwide
• The company is actively hiring and anticipates continued revenue growth and team growth in the coming years
• Bittner is excited about the continued drive towards having physiologically more relevant model systems
• Bittner sees AI and machine learning as powerful tools that will be increasingly adopted in a drug discovery context and predicts that all drugs reaching the market will have had some form of AI involvement in the future
• Bittner is concerned about human health being jeopardized by conflicts between different geopolitical blocks and the risk management that companies need to consider
• Bittner is excited about the transformation of the industry and the opportunities that lie ahead with new technologies and techniques that can bring more and better drugs to patients faster

Send us a text

In this episode of the Life Science Success podcast, my guest is Bremer Louw.  Bremer is the vice president of operations at Bioforum, a data focused CRO. He has been in the clinical research industry for over 15 years and has extensive experience in data management and biostatistics programming.

Bremer Louw, VP of Operations at Bioform, discusses the company's focus on meeting customer needs and building solutions for complex problems. He also expresses concerns about the pace of innovation and the ethical and regulatory implications of machine learning and artificial intelligence in the life sciences industry. Louw emphasizes the importance of small successes and momentum in achieving larger goals.

• Bioform is a smaller, more nimble organization with a different culture than larger companies like IQVIA.
• Bioform is attentive to customers' needs and works to meet them on an individual basis.
• Bremer Louw, the VP of Operations at Bioform, is responsible for overseeing operational metrics, professional services, quality, business development, and innovation.
• Bioform works with both drug and diagnostic companies.
• Louw is concerned about the pace of innovation in the industry and the ethical and regulatory implications of machine learning and artificial intelligence.
• Louw emphasizes the importance of small successes and momentum in achieving larger goals.

Send us a text

In this episode of Life Science Success my guest is Siddhartha Shrivastava, Ph.D.  Sidd is the 
Vice President, Head of CMC and Global Technical Operations at Cue Biopharma.  He is a proven leader and well-published scientific-technical operations professional with experience in leading research, early to late-stage process development, commercial launch, cGMP commercial manufacturing (DS/DP), due diligence of new targets and facility acquisition, end to end supply chain management, and CMO management for bio-therapeutic drugs.